Why do even the most sophisticated tech investors often shy away from biotech? It often seems like an impenetrable maze of regulations, clinical trials, and complex science.

Enter Hannu Rajaniemi, who brings a refreshingly clear perspective to the world of biotech. As both the CEO of Helix Nanotechnologies and a bestselling science fiction author, he bridges the gap between cutting-edge science and practical business insights. In conversation with Mercury CEO Immad Akhund and Lima co-founder Raj Suri, Rajaniemi reveals the real dynamics shaping the future of medicine.

The discussion unpacks several game-changing trends that every tech entrepreneur should understand: how AI reasoning models are revolutionizing research and development, why global competition is making traditional biotech business models obsolete, and what really matters when evaluating biotech investments.